Subacute cutaneous lupus erythematosus

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
JAK inhibitor 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 1 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-504863-17-00 11 countries 2024 n=205
    Recruiting

Phase II/III

1 trial
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505634-94-00 11 countries 2023 n=217
    Recruiting

Phase II

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    DEUCRAVACITINIB
    2023-504161-22-00 3 countries 2021 n=36
    Ended

Phase I (Other)

1 trial
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2022-503009-39-00 6 countries 2024 n=37
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Biogen Idec Research Limited Commercial 2 Phase II/III, Phase III 2
Bristol-Myers Squibb Services Unlimited Company Commercial 2 Phase I (Other), Phase II 0
New trials by year
2021
1
2023
1
2024
2
← All indication landscapes